By: Benzinga
April 01, 2013 at 13:13 PM EDT
Leerink Analyst Says Prescriptions for Amarin's Vascepa 'Tracking Well'
Leerink Swann's Joseph Schwartz issued a note earlier Monday suggesting prescriptions for Amarin's (NASDAQ: AMRN ) Vascepa are "tracking well." The analyst said recent IMS data showed Vascepa prescriptions through the eleventh week are at 1,504 per week. Refills are at 13 percent. Schwartz called this level of prescriptions to
Related Stocks:
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates Bots go here